CytomX reports ADC data in late-line colorectal cancer; FDA OKs Cosentyx label expansionnews2026-03-16T13:38:35+00:00March 16th, 2026|Endpoints News|
Y-mAbs terminates radiopharma trial; GSK gets expanded use for Arexvynews2026-03-13T13:48:06+00:00March 13th, 2026|Endpoints News|
UCB says Bimzelx tops Skyrizi in trial; Xenon, Dianthus set share salesnews2026-03-11T14:52:55+00:00March 11th, 2026|Endpoints News|
Ascletis touts GLP-1 quarterly dosing data; Mineralys apnea Phase 2 missesnews2026-03-10T15:02:46+00:00March 10th, 2026|Endpoints News|
AbbVie, Gubra post obesity data; Regeneron obesity drug succeeds in Chinanews2026-03-09T15:17:36+00:00March 9th, 2026|Endpoints News|
Solid Biosciences gets $240M for pipeline; Roche expounds on lupus datanews2026-03-06T15:35:55+00:00March 6th, 2026|Endpoints News|
Bayer continues trimming workforce; AnaptysBio’s spinoff is namednews2026-03-04T15:56:40+00:00March 4th, 2026|Endpoints News|
Prolium’s $50M Series A raise; COUR Pharma touts liver drug follow-upnews2026-03-03T15:32:03+00:00March 3rd, 2026|Endpoints News|
Aardvark’s stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADCnews2026-03-02T16:14:18+00:00March 2nd, 2026|Endpoints News|
Ginkgo divests biosecurity arm; J&J’s early prostate cancer datanews2026-02-27T15:14:31+00:00February 27th, 2026|Endpoints News|
